Christopher Haqq, EVP, R&D & Chief Scientific Of at Atara Biotherapeutics, Inc. (ATRA), sold 27,950 shares at $15.46 ($432K) on 2017-02-09, disclosed to the SEC on 2017-02-10.
Open-market sale of $432k ATRA by EVP, R&D & Chief Scientific Of. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Something here stands out, but not much.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $15.46 | 13,975 | $216K | 50.0% |
| 2 | $15.46 | 13,975 | $216K | 50.0% |
| Total | $15.46 avg | 27,950 | $432K | 100% |
| Filing → |
| ATRA | SELL | 2019-02-08 | $956K | — | Filing → |
| ATRA | SELL | 2018-11-15 | $26K | — | Filing → |
| ATRA | SELL | 2018-09-27 | $582K | — | Filing → |